TY - JOUR
T1 - Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer
AU - Serebriiskii, Ilya G.
AU - Pavlov, Valerii A.
AU - Andrianov, Grigorii V.
AU - Litwin, Samuel
AU - Basickes, Stanley
AU - Newberg, Justin Y.
AU - Frampton, Garrett M.
AU - Meyer, Joshua E.
AU - Golemis, Erica A.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/11/24
Y1 - 2023/11/24
N2 - Somatic PTEN mutations are common and have driver function in some cancer types. However, in colorectal cancers (CRCs), somatic PTEN-inactivating mutations occur at a low frequency (~8–9%), and whether these mutations are actively selected and promote tumor aggressiveness has been controversial. Analysis of genomic data from ~53,000 CRCs indicates that hotspot mutation patterns in PTEN partially reflect DNA-dependent selection pressures, but also suggests a strong selection pressure based on protein function. In microsatellite stable (MSS) tumors, PTEN alterations co-occur with mutations activating BRAF or PI3K, or with TP53 deletions, but not in CRC with microsatellite instability (MSI). Unexpectedly, PTEN deletions are associated with poor survival in MSS CRC, whereas PTEN mutations are associated with improved survival in MSI CRC. These and other data suggest use of PTEN as a prognostic marker is valid in CRC, but such use must consider driver mutation landscape, tumor subtype, and category of PTEN alteration.
AB - Somatic PTEN mutations are common and have driver function in some cancer types. However, in colorectal cancers (CRCs), somatic PTEN-inactivating mutations occur at a low frequency (~8–9%), and whether these mutations are actively selected and promote tumor aggressiveness has been controversial. Analysis of genomic data from ~53,000 CRCs indicates that hotspot mutation patterns in PTEN partially reflect DNA-dependent selection pressures, but also suggests a strong selection pressure based on protein function. In microsatellite stable (MSS) tumors, PTEN alterations co-occur with mutations activating BRAF or PI3K, or with TP53 deletions, but not in CRC with microsatellite instability (MSI). Unexpectedly, PTEN deletions are associated with poor survival in MSS CRC, whereas PTEN mutations are associated with improved survival in MSI CRC. These and other data suggest use of PTEN as a prognostic marker is valid in CRC, but such use must consider driver mutation landscape, tumor subtype, and category of PTEN alteration.
UR - http://www.scopus.com/inward/record.url?scp=85178098553&partnerID=8YFLogxK
UR - https://doi.org/10.1038/s41525-023-00384-7
U2 - 10.1038/s41525-023-00384-7
DO - 10.1038/s41525-023-00384-7
M3 - Article
C2 - 38001126
SN - 2056-7944
VL - 8
SP - 40
JO - npj Genomic Medicine
JF - npj Genomic Medicine
IS - 1
M1 - 40
ER -